Literature DB >> 6288502

Activities of various enzymes of pyrimidine nucleotide and DNA syntheses in normal and neoplastic human tissues.

Y Maehara, H Nakamura, Y Nakane, K Kawai, M Okamoto, S Nagayama, T Shirasaka, S Fujii.   

Abstract

The activities of the key enzymes of pyrimidine nucleotide and DNA syntheses in 43 human tumors and 28 normal human tissues were investigated. The activities of cytidine triphosphate synthetase, deoxycytidine monophosphate deaminase, uridine kinase, thymidine kinase, thymidine monophosphate kinase and DNA polymerase were markedly increased in tumor tissues, compared with those in the corresponding normal tissues, while the activities of deoxycytidine kinase, cytidine deaminase and deoxycytidine deaminase were only slightly increased. The use of thymidine and deoxyuridine as substrates of human pyrimidine nucleoside phosphorylase gave 1 to 2 orders of magnitude higher activity than that of uridine.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6288502

Source DB:  PubMed          Journal:  Gan        ISSN: 0016-450X


  13 in total

1.  Potentiation of the chemotherapeutic action of 5'-deoxy-5-fluorouridine in combination with guanosine and related compounds.

Authors:  M Iigo; M Miwa; H Ishitsuka; K Nitta
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  Sequence and expression of the dCMP deaminase gene (DCD1) of Saccharomyces cerevisiae.

Authors:  E M McIntosh; R H Haynes
Journal:  Mol Cell Biol       Date:  1986-05       Impact factor: 4.272

3.  Inhibitory effect of 2'-substituted nucleosides on hepatitis C virus replication correlates with metabolic properties in replicon cells.

Authors:  Joanne E Tomassini; Krista Getty; Mark W Stahlhut; Sung Shim; Balkrishen Bhat; Anne B Eldrup; Thazha P Prakash; Steven S Carroll; Osvaldo Flores; Malcolm MacCoss; Daniel R McMasters; Giovanni Migliaccio; David B Olsen
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

4.  In vitro study on intrathecal use of 5-fluoro-2'-deoxyuridine (FdUrd) for meningeal dissemination of malignant brain tumors.

Authors:  M Yamada; H Nakagawa; M Fukushima; K Shimizu; T Hayakawa; K Ikenaka
Journal:  J Neurooncol       Date:  1998-04       Impact factor: 4.130

5.  Difference in thymidylate synthetase activity in involved nodes compared with primary tumor in breast cancer patients.

Authors:  K Komaki; Y Kamamura; Y Ohmine; M Sasa; K Tanaka; H Inoue; T Uyama; T Morimoto; Y Monden
Journal:  Breast Cancer Res Treat       Date:  1995-08       Impact factor: 4.872

6.  Effect of guanosine on antitumor activity of fluorinated pyrimidines against P 388 leukemia.

Authors:  M Iigo; A Hoshi
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

7.  Thymidylate synthase gene expression in primary tumors predicts activity of s-1-based chemotherapy for advanced gastric cancer.

Authors:  Hiroya Takiuchi; Shin-Ichiro Kawabe; Masahiro Gotoh; Ken-Ichi Katsu
Journal:  Gastrointest Cancer Res       Date:  2007-09

8.  Potentiation of the antitumor activity of 5-trifluoromethyl-2'-deoxyuridine by the use of depot forms of the parent compound.

Authors:  S Takeda; K Wierzba; J Yamashita; H Matsumoto; H Satake; Y Yamada; N Unemi; Y Wataya; H Hayatsu
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine in Solid Tumors.

Authors:  Colin R Young; Stephen Adler; Janet F Eary; M Liza Lindenberg; Paula M Jacobs; Jerry Collins; Shivaani Kummar; Karen A Kurdziel; Peter L Choyke; Esther Mena
Journal:  J Nucl Med       Date:  2018-11-02       Impact factor: 10.057

10.  A nucleoside anticancer drug, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (TAS106), sensitizes cells to radiation by suppressing BRCA2 expression.

Authors:  Shunsuke Meike; Tohru Yamamori; Hironobu Yasui; Masato Eitaki; Akira Matsuda; Masami Morimatsu; Masakazu Fukushima; Yasundo Yamasaki; Osamu Inanami
Journal:  Mol Cancer       Date:  2011-07-28       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.